Abstract
Patients with cancer-related anorexia (CRA) have a lack of appetite, early satiety, taste changes, poor performance status, and diminished quality of life. Megestrol acetate is a standard treatment for CRA. Recently, olanzapine has been reported to be effective for treating refractory nausea and vomiting induced by chemotherapy in patients with cancer. A clinical trial has found that the combination of megestrol acetate and olanzapine is effective for patients with CRA. In this article we describe the treatment of CRA using olanzapine.
